AOP Health is advancing its clinical research program focused on myeloproliferative neoplasms, a group of rare blood cancers. The company presented results from two studies at the 67th American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida, offering new insights into treatment approaches.
The ROP-ET study evaluated ropeginterferon alfa-2b in patients with essential thrombocythemia (ET), a condition characterized by excessive platelet production. This prospective, multicenter, single-arm phase III trial assessed the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to tolerate existing cytoreductive therapies.
The BESREMi-PASS study examined the real-world performance of ropeginterferon alfa-2b in patients with polycythemia vera (PV), a rare blood cancer involving increased production of red and white blood cells and platelets due to abnormal bone marrow stem cells.
Both studies contribute valuable data on how ropeginterferon alfa-2b can support patients with these chronic blood cancers.
Martin Steinhart, CEO of AOP Health, stated that the company’s mission is to address unmet medical needs in rare diseases. He emphasized that ongoing investment in research and development underpins their commitment to advancing treatments and sharing new findings with the scientific community.
Ropeginterferon alfa-2b is the first interferon therapy approved in the European Union for treating polycythemia vera without symptomatic splenomegaly. It is a long-acting, mono-pegylated proline interferon administered subcutaneously via a pre-filled pen every two to four weeks, allowing for patient self-administration.
Leave a Reply